TrialsgrambetaRCTs are beautiful
ESC Congress 2026Presentato sab 29 ago · 08:30 CESTHot Line 2Tutti gli studi Hot Line →

AMUNDSEN

2026

Acute Myocardial Infarction Upbound to PCI Immediately (STEMI) or in the Next Three Days (NSTEMI), and Randomized to Subcutaneous Evolocumab or Normal Strategies to Reach Guidelines LDL Objectives in the Real-world

In 2,161 patients with acute myocardial infarction undergoing PCI, evolocumab started before PCI increased achievement of an LDL-C reduction of ≥50 % to below 1.4 mmol/L at 12 months compared with standard lipid-lowering care.

Risultato

Efficacia: Achievement of both a ≥50% LDL-C reduction from baseline and LDL-C <1.4 mmol/L (55 mg/dL) at 12 months; main clinical endpoint the composite of all-cause death or unplanned cardiovascular hospitalisation at 12 monthsadjusted OR 5,54 (IC 95% 4,50-6,82) · P < 0,001

Sotto 1 a favore di standard lipid-lowering care, sopra 1 a favore di evolocumab started before PCI.

Tassi di eventi
Differenza assoluta
42,0 punti
NNT
3

La differenza assoluta e l’NNT sono derivati dai tassi di eventi.

Riportato inoltre: Primary lipid endpoint met: median LDL-C at 6 weeks 16 vs 56 mg/dL. No clinical benefit: death or unplanned cardiovascular hospitalisation at 12 months 159/1087 (14.6%) vs 165/1074 (15.4%), adjusted OR 0.94 (95% CI 0.73–1.19), p=0.59

Pubblicazione originale
Sottotema
PCSK9 inhibition in ACS
Disegno
International, investigator-initiated Phase IV PROBE RCT, 1:1, first evolocumab dose given before PCI, 12-month primary follow-up (clinical follow-up continuing to 2028)
Rilevanza
Importante: uno dei diversi pilastri.
Fonte
Montalescot G, Ferrari E, Souteyrand G, et al. JAMA. 2026; published online 29 August.doi 10.1001/jama.2026.17302

Discussione e critica

Giving the PCSK9 antibody before the wire crosses does what the pharmacology promises: four in five reach the guideline target at a year against two in five, with a median LDL-C of 16 mg/dL at six weeks. What it does not do, over twelve months, is change death or cardiovascular readmission: an open-label trial powered for a laboratory endpoint, not for events. The lipid result is the argument for starting early; the clinical arm is the reminder that a year is short for a curve that separates late.

Discusso nei podcast